Literature DB >> 23997244

Synthesis and Pharmacological Evaluation of 4-Iminothiazolidinones for Inhibition of PI3 Kinase.

Jo-Anne Pinson1, Oleg Schmidt-Kittler, Mark Frazzetto, Zhaohua Zheng, Ian G Jennings, Kenneth W Kinzler, Bert Vogelstein, David K Chalmers, Philip E Thompson.   

Abstract

The thiazolidinedione, compound 1, has previously shown pan-inhibition of the phosphoinositide 3-kinase (PI3K) class I isoforms. We hypothesized the derivatization of the thiazolidinedione core of compound 1 could introduce isoform selectivity. We report the synthesis, characterization, and inhibitory activity of a novel series of 4-iminothiazolidin-2-ones for inhibition of the class I PI3K isoforms. Their synthesis was successfully achieved by multiple pathways described in this paper. Initial in vitro data of 28 analogues demonstrated poor inhibition of all class I PI3K isoforms. However, we identified an alternate target, the phosphodiesterases, and present preliminary screening results showing improved inhibitory activity.

Entities:  

Year:  2012        PMID: 23997244      PMCID: PMC3755381          DOI: 10.1071/CH12140

Source DB:  PubMed          Journal:  Aust J Chem        ISSN: 0004-9425            Impact factor:   1.321


  8 in total

1.  Novel GSK-3beta inhibitors from sequential virtual screening.

Authors:  Hye-Jung Kim; Hyunah Choo; Yong Seo Cho; Kyoung Tai No; Ae Nim Pae
Journal:  Bioorg Med Chem       Date:  2007-10-22       Impact factor: 3.641

2.  Impact of impurity on kinetic estimates from transport and inhibition studies.

Authors:  Pablo González; James E Polli
Journal:  J Pharmacol Exp Ther       Date:  2008-04-28       Impact factor: 4.030

3.  New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays.

Authors:  Jonathan B Baell; Georgina A Holloway
Journal:  J Med Chem       Date:  2010-04-08       Impact factor: 7.446

4.  An Invitation to Open Innovation in Malaria Drug Discovery: 47 Quality Starting Points from the TCAMS.

Authors:  Félix Calderón; David Barros; José María Bueno; José Miguel Coterón; Esther Fernández; Francisco Javier Gamo; José Luís Lavandera; María Luisa León; Simon J F Macdonald; Araceli Mallo; Pilar Manzano; Esther Porras; José María Fiandor; Julia Castro
Journal:  ACS Med Chem Lett       Date:  2011-08-03       Impact factor: 4.345

5.  Blockade of PI3Kgamma suppresses joint inflammation and damage in mouse models of rheumatoid arthritis.

Authors:  Montserrat Camps; Thomas Rückle; Hong Ji; Vittoria Ardissone; Felix Rintelen; Jeffrey Shaw; Chiara Ferrandi; Christian Chabert; Corine Gillieron; Bernard Françon; Thierry Martin; Denise Gretener; Dominique Perrin; Didier Leroy; Pierre-Alain Vitte; Emilio Hirsch; Matthias P Wymann; Rocco Cirillo; Matthias K Schwarz; Christian Rommel
Journal:  Nat Med       Date:  2005-08-28       Impact factor: 53.440

6.  Structural modification studies of 3-piperonylsydnone. 2. Synthesis of piperonyl-substituted hydantoin, thiohydantoin, thiazolidinedione, rhodanine, imidazolinone, and related compounds.

Authors:  W H Burton; W L Budde; C C Cheng
Journal:  J Med Chem       Date:  1970-09       Impact factor: 7.446

7.  Rhodanine derivatives as novel inhibitors of PDE4.

Authors:  Mark W Irvine; Graham L Patrick; Justin Kewney; Stuart F Hastings; Simon J MacKenzie
Journal:  Bioorg Med Chem Lett       Date:  2008-02-02       Impact factor: 2.823

8.  Thiazolidinedione-based PI3Kα inhibitors: an analysis of biochemical and virtual screening methods.

Authors:  Jo-Anne Pinson; Oleg Schmidt-Kittler; Jiuxiang Zhu; Ian G Jennings; Kenneth W Kinzler; Bert Vogelstein; David K Chalmers; Philip E Thompson
Journal:  ChemMedChem       Date:  2011-01-04       Impact factor: 3.466

  8 in total
  1 in total

Review 1.  5-Ene-4-thiazolidinones - An efficient tool in medicinal chemistry.

Authors:  Danylo Kaminskyy; Anna Kryshchyshyn; Roman Lesyk
Journal:  Eur J Med Chem       Date:  2017-09-20       Impact factor: 6.514

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.